Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2%. (June 2019) - Naumann, U; Moll, A; Schleehauf, D; Lutz, KT; Schmidt, W; Jaeger, H; Funke, B; Witte, V